Several studies have shown that reducing the dose of CDK4/6i due to toxicity, such as neutropenia, did not worsen the efficacy of the treatment, and patients with a reduced dose of CDK4/6i responded as well as patients with a full dose [12,13]. The gene discussed is CDK4; the disease is neutropenia.